XBiotech to Provide First Quarter 2017 Business Update
April 28 2017 - 8:00AM
XBiotech Inc. (NASDAQ:XBIT) announced today it will host a
conference call and live audio webcast on Thursday, May 4,
2017, at 8:30 a.m. Eastern Time, to provide an overview of its
corporate and clinical activities. The call will encompass
developments during the first quarter ended March 31, 2017.
Conference Call Information: Interested
participants and investors may access the conference call by
dialing:
- 1 (844) 249-9385 (U.S.)
- 1 (270) 823-1533 (International)
- Conference ID: 15848733
A live audio webcast will also be accessible via
the Investors section of
the XBiotech website www.xbiotech.com. The webcast
replay will remain available for 90 days.
A telephonic replay of the conference call can
be accessed by dialing 1 (855) 859-2056 (U.S.) or 1 (404) 537-3406,
and providing the Conference ID: 15848733. The telephonic
replay will be available for 24 hours beginning at 11:29 p.m.
Eastern Time on May 4, 2017.
About XBiotech XBiotech is
a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of
therapeutic antibodies based on its True Human™ proprietary
technology. XBiotech currently is advancing a robust pipeline of
antibody therapies to redefine the standards of care in oncology,
inflammatory conditions and infectious diseases. Headquartered in
Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more
rapidly, cost-effectively and flexibly produce new therapies
urgently needed by patients worldwide.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements, including with respect to the proposed offering of
common shares, declarations regarding management's beliefs and
expectations that involve substantial risks and uncertainties. In
some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "would," "could,"
"expects," "plans," "contemplate," "anticipates," "believes,"
"estimates," "predicts," "projects," "intend" or "continue" or the
negative of such terms or other comparable terminology, although
not all forward-looking statements contain these identifying words.
Forward-looking statements are subject to inherent risks and
uncertainties in predicting future results and conditions that
could cause the actual results to differ materially from those
projected in these forward-looking statements. These risks and
uncertainties are subject to the disclosures set forth in the "Risk
Factors" section of certain of our SEC filings. Forward-looking
statements are not guarantees of future performance, and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Apr 2024 to May 2024
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From May 2023 to May 2024